Trials / Completed
CompletedNCT00619164
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 240 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese patients with acute coronary syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | E5555 | E5555, 50 mg (tablet), taken orally, once a day. |
| DRUG | E5555 | E5555, 100 mg (tablet), taken orally, once a day. |
| DRUG | E5555 | E5555, 200 mg (tablet), taken orally, once a day. |
| DRUG | Placebo | Placebo tablet taken orally, once a day. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-09-01
- First posted
- 2008-02-20
- Last updated
- 2013-05-13
Locations
33 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00619164. Inclusion in this directory is not an endorsement.